CL2007002693A1 - Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras. - Google Patents

Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras.

Info

Publication number
CL2007002693A1
CL2007002693A1 CL200702693A CL2007002693A CL2007002693A1 CL 2007002693 A1 CL2007002693 A1 CL 2007002693A1 CL 200702693 A CL200702693 A CL 200702693A CL 2007002693 A CL2007002693 A CL 2007002693A CL 2007002693 A1 CL2007002693 A1 CL 2007002693A1
Authority
CL
Chile
Prior art keywords
pirazolopirimidina
tiazol
anxiety
obesity
hypertension
Prior art date
Application number
CL200702693A
Other languages
English (en)
Spanish (es)
Inventor
Chen Chafiq Hamdouchi Zhaogen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2007002693A1 publication Critical patent/CL2007002693A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200702693A 2006-09-20 2007-09-20 Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras. CL2007002693A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20

Publications (1)

Publication Number Publication Date
CL2007002693A1 true CL2007002693A1 (es) 2008-04-18

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702693A CL2007002693A1 (es) 2006-09-20 2007-09-20 Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras.

Country Status (33)

Country Link
US (1) US8030304B2 (OSRAM)
EP (1) EP2094709B1 (OSRAM)
JP (1) JP5161226B2 (OSRAM)
KR (1) KR101088239B1 (OSRAM)
CN (1) CN101516887B (OSRAM)
AR (1) AR062886A1 (OSRAM)
AT (1) ATE481405T1 (OSRAM)
AU (1) AU2007297421B2 (OSRAM)
BR (1) BRPI0717023B8 (OSRAM)
CA (1) CA2663511C (OSRAM)
CL (1) CL2007002693A1 (OSRAM)
CR (1) CR10682A (OSRAM)
CY (1) CY1110854T1 (OSRAM)
DE (1) DE602007009305D1 (OSRAM)
DK (1) DK2094709T3 (OSRAM)
EA (1) EA015179B1 (OSRAM)
ES (1) ES2350282T3 (OSRAM)
HR (1) HRP20100516T1 (OSRAM)
IL (1) IL197614A (OSRAM)
MA (1) MA30798B1 (OSRAM)
MX (1) MX2009003125A (OSRAM)
MY (1) MY146388A (OSRAM)
NO (1) NO20091489L (OSRAM)
NZ (1) NZ575572A (OSRAM)
PE (1) PE20081377A1 (OSRAM)
PL (1) PL2094709T3 (OSRAM)
PT (1) PT2094709E (OSRAM)
RS (1) RS51545B (OSRAM)
SI (1) SI2094709T1 (OSRAM)
TN (1) TN2009000095A1 (OSRAM)
TW (1) TWI402269B (OSRAM)
UA (1) UA96458C2 (OSRAM)
WO (1) WO2008036579A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2011003529A (es) 2008-10-02 2011-04-21 Lilly Co Eli Compuestos de tiazolil-pirazolopirimidina como intermediarios sinteticos y procesos sinteticos relacionados.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN106102740A (zh) * 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
US11077108B2 (en) 2016-09-07 2021-08-03 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CA3064445A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
EP3784233B1 (en) 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
EP3984523B1 (en) 2018-12-07 2025-09-03 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
WO2021062246A1 (en) 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
AR120649A1 (es) * 2019-12-04 2022-03-09 Neurocrine Biosciences Inc Antagonistas del receptor de crf y métodos de uso
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
EP4175572A4 (en) * 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2022046905A1 (en) 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
KR20240109274A (ko) * 2021-11-19 2024-07-10 스프루스 바이오사이언시스 인코포레이티드 틸다서폰트의 결정질 조성물 및 이의 사용 및 제조 방법
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
PL191271B1 (pl) * 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
PL195762B1 (pl) * 1996-07-24 2007-10-31 Bristol Myers Squibb Pharma Co Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku
ES2294800T3 (es) * 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ATE347553T1 (de) * 1999-09-30 2006-12-15 Neurogen Corp Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
DE60218434T2 (de) 2001-03-13 2007-11-08 Bristol-Myers Squibb Pharma Co. 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
RU2394035C2 (ru) 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним

Also Published As

Publication number Publication date
ATE481405T1 (de) 2010-10-15
CA2663511C (en) 2012-12-04
RS51545B (sr) 2011-06-30
EP2094709A1 (en) 2009-09-02
CN101516887B (zh) 2011-11-02
CR10682A (es) 2009-08-13
MA30798B1 (fr) 2009-10-01
ES2350282T3 (es) 2011-01-20
BRPI0717023A2 (pt) 2014-03-11
TWI402269B (zh) 2013-07-21
PL2094709T3 (pl) 2011-02-28
UA96458C2 (ru) 2011-11-10
WO2008036579A1 (en) 2008-03-27
EP2094709B1 (en) 2010-09-15
CY1110854T1 (el) 2015-06-10
US8030304B2 (en) 2011-10-04
BRPI0717023B1 (pt) 2019-11-19
AU2007297421B2 (en) 2012-03-08
DE602007009305D1 (de) 2010-10-28
IL197614A0 (en) 2009-12-24
HK1132505A1 (en) 2010-02-26
PT2094709E (pt) 2010-10-04
JP5161226B2 (ja) 2013-03-13
AR062886A1 (es) 2008-12-10
TW200821312A (en) 2008-05-16
HRP20100516T1 (hr) 2010-10-31
US20100222339A1 (en) 2010-09-02
PE20081377A1 (es) 2008-09-18
KR101088239B1 (ko) 2011-11-30
CN101516887A (zh) 2009-08-26
MX2009003125A (es) 2009-05-28
NO20091489L (no) 2009-04-16
EA015179B1 (ru) 2011-06-30
IL197614A (en) 2012-10-31
CA2663511A1 (en) 2008-03-27
NZ575572A (en) 2011-10-28
AU2007297421A1 (en) 2008-03-27
KR20090052366A (ko) 2009-05-25
SI2094709T1 (sl) 2011-01-31
BRPI0717023B8 (pt) 2021-05-25
TN2009000095A1 (en) 2010-08-19
DK2094709T3 (da) 2010-12-06
MY146388A (en) 2012-08-15
JP2010504344A (ja) 2010-02-12
EA200970303A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
CL2007002693A1 (es) Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras.
CL2008003339A1 (es) Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia.
CL2007002348A1 (es) Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
CL2007003183A1 (es) Compuestos biciclicos puenteados; y composicion farmaceutica, util para el tratamiento de trastornos del apetito, diabetes y obesidad entre otros.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2007002650A1 (es) Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
CL2007001885A1 (es) Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis.
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2007003755A1 (es) Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
CL2008001215A1 (es) Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer.
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2011000478A1 (es) Compuestos derivados de 2-imidazol-propanamida sustituidos, activadores de glucoquinasa; composicion farmaceutica, util para tratar o retrasar la progresion o aparacion de la diabetes tipo ii o trastornos relacionados con la diabetes.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2013003333A1 (es) Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.